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Abstract
Primary hepatic lymphoma (PHL) is a rare
malignancy. We aimed to assess the clinical
profile, outcome and prognostic factors in PHL
through the Rare Cancer Network (RCN). A
retrospective analysis of 41 patients was per-
formed. Median age was 62 years (range, 23-
86 years) with a male-to-female ratio of
1.9:1.0. Abdominal pain or discomfort was the
most common presenting symptom. Regarding
B-symptoms, 19.5% of patients had fever,
17.1% weight loss, and 9.8% night sweats. The
most common radiological presentation was
multiple lesions. Liver function tests were ele-
vated in 56.1% of patients. The most common
histopathological diagnosis was diffuse large
B-cell lymphoma (65.9%). Most of the patients
received Chop-like (cyclophosphamide, dox-
orubicin, vincristine, and prednisone) regi-
mens; 4 patients received radiotherapy (dose
range, 30.6-40.0 Gy). Median survival was 163
months, and 5- and 10-year overall survival
rates were 77 and 59%, respectively. The 5- and
10-year disease-free and lymphoma-specific
survival rates were 69, 56, 87 and 70%, respec-
tively. Multivariate analysis revealed that fever,
weight loss, and normal hemoglobin level were
the independent factors influencing the out-
come. In this retrospective multicenter RCN
study, patients with PHL had a relatively better
prognosis than that reported elsewhere.
Multicenter prospective studies are still war-
ranted to establish treatment guidelines, out-
come, and prognostic factors.
Introduction
Primary hepatic lymphoma (PHL) is a rare
malignancy, although secondary liver involve-
ment in patients with advanced stages of lym-
phoma is common. PHL represents 0.016% of
all non-Hodgkin’s lymphomas and 0.4% of all
extranodal lymphomas.1 Because of the low
number of reported cases, the disease is poorly
understood and few clinical studies have been
conducted to help elucidate the pathogenesis,
variability of the clinical presentation, natural
course of the disease, optimal therapy,
response to therapy, and survival.2,3
Regarding the exact definition of PHL, no
consensus has been achieved. Some reports
have been based on cases in which staging
investigations failed to show extrahepatic dis-
ease, whereas others have accepted cases as
being primary if the disease was confined to
the liver at presentation.4 The criteria for diag-
nosis defined by Lei are: i) symptoms caused
mainly by liver involvement at presentation; ii)
absence of distant lymphadenopathy, palpable
clinically at presentation or detected during
staging radiologic studies; and iii) absence of
leukemic blood involvement in the peripheral
blood smear.5
The pathogenesis is not clear but several
etiologic factors for PHL have been proposed
such as an increased incidence of PHL in
patients with hepatitis B and C virus infection
and exposure to chemicals.6-8 Most of the
patients diagnosed with PHL are middle-aged
men, majority of cases are diffuse large B-cell
type, and presenting complaints consists of
abdominal pain, fatigue, and constitutional
symptoms, hepatomegaly being frequent.9
Although there is little consistency in the lit-
erature regarding the treatment, options
include surgery, chemotherapy, radiation ther-
apy or combination of these modalities. The
reported median survival rates vary widely in
the literature, however, it is believed that the
prognosis for patients with PHL is dismal, with
early disease recurrence at extrahepatic sites
and short survival.5,9
The purpose of this study was to assess the
clinical profile, outcome and prognostic factors
in PHL in an attempt to gather additional infor-
mation on this rare entity through the Rare
Cancer Network (RCN).
Materials and Methods
A retrospective analysis of patients with PHL
diagnosed between 1977 and 2014 was per-
formed in the framework of RCN. Seven insti-
tutions within 5 countries of the RCN group
contributed cases of PHL, and 41 patients met
the criteria for PHL suggested by Lei.5 Patients
with splenic and bone marrow involvement
were excluded. This study was approved by
Mayo Foundation Institutional Review Board
and at each participating center independent-
ly. The medical records of all patients were
reviewed to identify patients and tumor char-
acteristics, treatment details, and follow-up
information. All original pathology reports
were reviewed using the World Health
Organization (WHO) classification of lym-
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phoma. The cut-off date for the survival study
was December 2014. The histologic slides were
not centrally reviewed.
Survival curves were computed using the
Kaplan-Meier method. The events were death
irrespective of cause for overall survival (OS)
and any relapse for disease-free survival
(DFS), and time was measured from the date
of diagnosis to the event. The lymphoma-spe-
cific survival (LSS) was calculated to the date
of death related to lymphoma from the date of
diagnosis. Log-rank and Wilcoxon tests were
used to determine prognostic factors and
assess differences between groups. Cox multi-
ple regression analysis was done for prognos-
tic factors having a P-value ≤0.25 in univariate
analyses. A P-value<0.05 was considered to be
significant. The statistical analyses were per-
formed using JMP v11 (SAS Corp., Cary, NC,
USA).
Results
Patients’ clinicopathological and laboratory
characteristics are summarized in Table 1.
Median age was 62 years (range, 23-86 years)
with a male-to-female ratio of 1.9:1.0 (27/14).
Median follow-up time was 116 months (range,
1-225 months). Abdominal pain or discomfort
was the most common presenting symptom,
and occurred in 22 patients (53.7%). The other
symptoms were fatigue (22.0%), jaundice
(14.6%), anorexia (14.6%), nausea and/or
vomiting (17.1%). Regarding the B-symptoms,
19.5% of patients had fever, 17.1% had weight
loss, and 9.8% had night sweats. Hepatomegaly
was found in 17.1% of patients, and
splenomegaly was less common (9.8%).
Thirteen patients (31.7%) had a history of pre-
existing liver disease, 6 patients had chronic
hepatitis (14.6%), 4 patients with cirrhosis
(9.8%), one patient had polycystic liver disease
(2.4%), and 4 patients were diagnosed after
liver transplantation (9.8%). The imaging
modalities used evolved over time and loca-
tion, most patients (63.4%) had computed
tomography (CT) or ultrasonography (56.1%),
and only 6 patients had positron emission
tomography-CT (14.6%). The most common
radiological presentation was multiple lesions
(53.7%) followed by solitary lesion (36.6%),
and diffuse infiltration was present in 7.3% of
patients. Liver function tests, including lactate
dehydrogenase, alkaline phosphatase and
bilirubin, were elevated in 56.1% of patients
who were tested. Hemoglobin levels in com-
plete blood count were lower than normal in 11
patients (26.8%) who were tested. Two
patients were Hepatitis B Ag positive, and 2
patients were HIV positive among patients who
were tested. Bone-marrow aspiration results
were recorded, and were normocellular if avail-
able (26 patients). The most common
histopathological diagnosis was diffuse large
B-cell lymphoma, which was observed in 27
patients (65.9%) according to the WHO classi-
fication system. Four tumors were marginal-
zone B-cell lymphoma, 3 were follicular lym-
phoma, 2 were precursor-cell lymphoblastic
lymphoma, 2 were mature T-cell lymphoma, 1
was malignant lymphoma small lymphocytic, 1
was small lymphocytic type T-cell lymphoma,
and 1 was Burkitt lymphoma. Combination
chemotherapy was administered to 30 patients
(73.2%). Chemotherapy regimens were differ-
ent according to the year of diagnosis and the
center. Most of the patients received CHOP-
like (cyclophosphamide, doxorubicin, vin-
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Table 1. Patients’ clinicopathological and laboratory characteristics.
Characteristics                                                                  No. (%)
Median age (at the time of diagnosis)                                    62 (range, 23-86 years)
Gender (male-to-female ratio)                                                               1.9:1.0
       Male                                                                                                      27 (65.9)
       Female                                                                                                 14 (34.1)
Presenting symptoms                                                                                       
        Abdominal pain or discomfort                                                       22 (53.7)
        Fatigue                                                                                                  9 (22.0)
        Jaundice                                                                                               6 (14.6)
        Anorexia                                                                                               6 (14.6)
        Nausea and/or vomiting                                                                   7 (17.1)
B symptoms                                                                                                        
       Fever                                                                                                     8 (19.5)
       Weight loss                                                                                          7 (17.1)
       Night sweats                                                                                         4 (9.8)
       Hepatomegaly                                                                                     7 (17.1)
       Splenomegaly                                                                                       4 (9.8)
Pre-existing liver disease                                                                                
        Chronic hepatitis                                                                                6 (14.6)
        Cirrhosis                                                                                               4 (9.8)
        Liver transplantation                                                                          4 (9.8)
        Polycystic liver disease                                                                      1 (2.4)
Radiological presentation                                                                               
       Multiple lesions                                                                                 22 (53.7)
       Solitary lesion                                                                                    15 (36.6)
       Diffuse infiltration                                                                             3 (7.3)
Histopathological diagnosis                                                                            
        Diffuse large B-cell lymphoma                                                      27 (65.9)
        Marginal zone B-cell lymphoma                                                       4 (9.8)
        Follicular lymphoma grade 1                                                            3 (7.3)
        Precursor cell lymphoblastic lymphoma                                       2 (4.9)
        Mature T-cell lymphoma                                                                    2 (4.9)
        Small lymphocytic type T-cell lymphoma                                       1 (2.4)
        Malignant lymphoma small lymphocytic                                        1 (2.4)
        Burkitt lymphoma                                                                                1 (2.4)
Treatment                                                                                                           
       Combination chemotherapy                                                           30 (73.2)
       Radiotherapy/chemo-radiotherapy                                                 4 (9.8)
       Surgery                                                                                                  4 (9.8)
Table 2. Chemotherapy regimens.
Regimen                                                                             No. (%)
CHOP-like                                                                                                             
         CHOP                                                                                                    8 (19.5)
         R-CHOP                                                                                                8 (19.5)
         CHOEP                                                                                                  1 (2.4)
         CHEP                                                                                                     1 (2.4)
         COP                                                                                                        1 (2.4)
         CHOP-Bleo                                                                                           1 (2.4)
Others                                                                                                          10 (24.4)
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; E, etoposide; Bleo, bleomycin.
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cristine, and prednisone) regimens (Table 2).
Four patients had also surgery, and only 4
patients were treated with radiotherapy or
chemo-radiotherapy. Total radiotherapy doses
ranged from 30.6-40.0 Gy in 1.8-2.0 Gy/fraction.
The median survival was 163 months, and 5-
and 10-year OS rates were 77% [95% confi-
dence interval (CI): 64-90%] and 59% (95% CI:
42-76%), respectively (Figure 1). The 5- and
10-year DFS and LSS rates were 69% (95% CI:
55-83%) and 56% (95% CI: 40-72%), and 87%
(95% CI: 76-98%) and 70% (95% CI: 53-87%),
respectively. In univariate analyses (log rank
test), patients with fever had a better outcome
(P=0.03). There was a positive trend (P=0.07)
for better OS in younger patients (≤62 years).
Gender, abdominal pain or discomfort, weight
loss, night sweats, preexisting liver disease,
multiple or diffuse lesions, elevated liver
enzymes, low hemoglobin levels,
hepatosplenomegaly, histopathology, and type
of treatment did not show any influence on the
outcome, most probably due to the small sam-
ple size (Table 3). In multivariate analysis
(Cox model), the presence of fever [relative
risk (RR)=2.16; P=0.005], absence of weight
loss (RR=1.22; P=0.048), and normal hemoglo-
bin level (RR=1.07; P=0.047) were the inde-
pendent factors influencing the outcome
(Table 4).
Discussion
To our knowledge, this is one of the largest
PHL series reported in the literature. PHL was
first described by Ata and colleagues in 1965.10
The published articles to date are mostly case
reports, and the largest series reported in the
English literature are those of El-Sharkawi and
colleagues11 with 22 patients and Page and col-
leagues9 with 24 patients. Also there are
review articles collecting and summarizing the
data about pathogenesis, clinical and patholog-
ical features, and the results of treatment of
PHL patients.2,12,13 Therefore, clinico-pathologi-
cal features of patients remain unclear, and we
proposed this study in an attempt to gather
additional information on this rare entity
through the RCN.
The age of presentation varies but PHL com-
monly presents in the 5th decade with a male
predominance according to the published liter-
ature. In our study, median age was 62 years,
which was slightly older than the literature
with a male predominance. Clinical presenta-
tion is generally nonspecific. The most com-
mon presenting symptom of PHL patients is
abdominal pain and the other symptoms
include fatigue, weight loss, jaundice, anorex-
ia, nausea, malaise, night sweats, and vomit-
ing.2 Abdominal pain or discomfort was the
most common presenting symptom in our
patients, and occurred in more than 50% of
patients. The B symptoms of fever, weight loss,
and night sweats were less common.
Hepatomegaly is common, and on examination
can be found in at least 50% of patients;2,5,13
however, only 17.1% of our patients had
hepatomegaly. Although enlargement of spleen
by lymphomatous involvement indicates a dis-
ease process, congestive splenomegaly may
occur because of hepatic dysfunction and por-
tal hypertension in PHL patients,2 and
splenomegaly was less common in our series
(9.8% of patients). 
The etiologic factors and the pathogenesis
are not clear, and there are several possible
factors that have been proposed. A number of
reports have suggested that PHL could evolve
in patients with chronic hepatitis, cirrhosis,
systemic lupus erythematosus, and in trans-
plant patients who were being treated with
immunosuppressive drugs.14-25 Thirteen
patients had a history of preexisting liver dis-
ease in our series (31.7%); 6 patients had
chronic hepatitis (14.6%), 4 patients cirrhosis
(9.8%), and 1 patient polycystic liver disease
(2.4%); 4 patients were diagnosed after liver
transplantation (9.8%). Lymphoproliferative
disorders after transplantation have been
developed in transplant recipients.26 The possi-
ble factor is continuous B-cell proliferation,
which is normally inhibited by T-lympho-
cytes.5,13 Acquired immune deficiency syn-
drome has also been suggested to play a role in
the pathogenesis of PHL.27 Two patients were
Hepatitis B Ag positive and 2 patients were HIV
positive among patients who were tested in
our study. 
PHL may radiologically present in 3 possible
ways in patients: a solitary lesion, multiple
lesions, or diffuse infiltration of the liver. The
most common presentation in the literature is
a solitary lesion, which occurs in 55-60% of
patients.2 In contrast to the previous reports,
the majority of our patients had multiple
lesions (53.7%). The complete blood count was
usually within normal range when lymphoma
was confined to the liver; and liver function
tests, including lactate dehydrogenase, alka-
line phosphatase and bilirubin, were usually
elevated.13 Liver function tests were elevated
in 56.1% of our patients who were tested.
Hemoglobin levels were lower than normal
limits in eleven patients. 
PHL is a pathologic diagnosis. Most of the
PHL cases (46-68%) reported in the literature
are diffuse large B-cell lymphoma, and other
histologies have been described in less than
5% of cases including diffuse mixed large and
small cell, lymphoblastic, diffuse immunoblas-
tic, diffuse histiocytic, mantle cell, and small
non-cleaved or Burkitt lymphoma.2,5,9
Immunohistochemistry, gene rearrange-
ment, karyotyping, and flow cytometry help in
further characterization of the tumor.2 The
most common histopathological diagnosis was
diffuse large B-cell lymphoma, which was
observed in 27 patients (65.9%) in our series.
T-cell PHL is less common and the described
subtypes include peripheral T-cell lymphoma,
anaplastic T-cell lymphoma, and hepato-
splenic T-cell lymphoma.28 Three of our
patients had T-cell lymphoma including two
mature T-cell and small lymphocytic type T-cell
lymphomas. There were also other subtypes
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Figure 1. Overall survival for 41 patients with primary hepatic lymphoma.
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Table 3. Univariate analyses in 41 patients with primary hepatic lymphoma.
Variable                                                              No.           5-year OS, %         95% CI              10-year OS,%          95% CI             P value*
All patients                                                                               41                            77                           64-90                                 59                             42-76                             
Age                                                                                                                                                                                                                                    
      >62                                                                                     21                            70                           50-90                                 49                             25-73                         0.07
      ≤62                                                                                     20                            84                          68-100                                69                             46-92                             
Gender                                                                                                                                                                                                                                                               
       Male                                                                                   27                            77                           61-93                                 60                             39-81                         0.90
       Female                                                                              14                            79                          57-100                                57                             27-87                             
Surgery                                                                                                                                                                                                                                                              
      Yes                                                                                      4                            100                              -                                    100                                -                             0.12
      No                                                                                       37                            75                           61-89                                 56                             38-74                             
Hemoglobin level                                                                                                                                                                                                                                             
       Normal                                                                              30                            86                           73-99                                 65                             45-85                         0.13
       Lower than normal                                                         11                            55                           26-85                                 44                             14-74                             
Liver function tests                                                                                                                                                                                                                                        
      Normal                                                                              18                            78                           59-97                                 69                             46-92                         0.86
      Elevated                                                                            23                            77                           59-95                                 52                             29-75                             
Radiological presentation                                                                                                                                                                                                                             
       Solitary                                                                              15                            71                           47-95                                 71                             47-95                         0.52
       Multiple or diffuse                                                         26                            80                           64-96                                 54                             32-76                             
Pre-existing liver disease                                                                                                                                                                                                                             
      Yes                                                                                     13                            76                           52-99                                 63                             33-93                         0.86
      No                                                                                       28                            78                           62-94                                 58                             38-79                             
Splenomegaly                                                                                                                                                                                                                                                   
       Yes                                                                                      4                             38                            0-94                                  38                              0-94                          0.37
       No                                                                                       37                            81                           68-94                                 61                             43-79                             
Hepatomegaly                                                                                                                                                                                                                                                  
      Yes                                                                                      7                             71                          38-100                                54                             15-93                         0.78
      No                                                                                       34                            78                           64-92                                 60                             41-79                             
Night sweats                                                                                                                                                                                                                                                     
       Yes                                                                                      4                            100                              -                                     75                            33-100                        0.24
       No                                                                                       37                            75                           61-89                                 57                             39-75                             
Weight loss                                                                                                                                                                                                                                                      
      Yes                                                                                      7                             57                           20-94                                 57                             20-94                         0.14
      No                                                                                       34                            81                           68-94                                 59                             40-78                             
Fever                                                                                                                                                                                                                                                                  
       Yes                                                                                      8                            100                              -                                     86                            60-100                        0.03
       No                                                                                       33                            72                           56-88                                 53                             33-73                             
B-symptoms (night sweats, weight loss, fever)                                                                                                                                                                                     
      Yes                                                                                     13                            77                           54-99                                 68                             42-94                         0.67
      No                                                                                       28                            78                           62-94                                 54                             32-76                             
Nausea/vomiting                                                                                                                                                                                                                                              
       Yes                                                                                      7                             86                          60-100                                57                             20-94                         0.55
       No                                                                                       34                            75                           60-90                                 61                             42-80                             
Anorexia                                                                                                                                                                                                                                                            
      Yes                                                                                      6                             67                          29-100                                67                            29-100                        0.80
      No                                                                                       35                            79                           65-93                                 57                             38-76                             
Jaundice                                                                                                                                                                                                                                                             
       Yes                                                                                      6                             83                          53-100                                83                            53-100                        0.88
       No                                                                                       35                            76                           62-90                                 54                             35-73                             
Fatigue                                                                                                                                                                                                                                                              
      Yes                                                                                      9                             78                          51-100                                47                             10-84                         0.19
      No                                                                                       32                            77                           62-92                                 63                             44-82                             
Abdominal pain or discomfort                                                                                                                                                                                                                      
       Yes                                                                                     22                            72                           53-91                                 49                             26-72                         0.25
       No                                                                                       19                            83                          66-100                                74                             51-97                             
Treatment modality                                                                                                                                                                                                                                        
      Chemotherapy alone                                                     26                            77                           61-93                                 61                             40-82                         0.59
      Other                                                                                 15                            79                          58-100                                56                             26-86                             
Histopathology                                                                                                                                                                                                                                                 
       Diffuse large B-cell                                                        27                            81                           66-96                                 65                             45-85                         0.69
       Others                                                                               14                            71                           47-95                                 45                             12-78
*Log rank test. OS, overall survival; CI, confidence interval.                           
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including marginal zone B-cell lymphoma in 4
patients, follicular lymphoma grade 1 in 3
patients, precursor cell lymphoblastic lym-
phoma in 2 patients, malignant lymphoma
small lymphocytic type in 1 patient, and Burkitt
lymphoma in 1 patient. The tumor may have a
nodular or diffuse growth pattern microscopi-
cally in which lymphoma cells expand into the
liver parenchyma.29
The optimal therapy is still unclear and
treatment options include surgery, chemother-
apy, radiation therapy, or combination of these
therapies.2 Surgical resection might be per-
formed for patients with localized disease with
good results.30 Past indications for surgical
treatment have included localized disease,
which can be completely resected, or for
debulking prior to chemotherapy.13 However,
there may be a bias towards better results in
patients treated surgically since they had a
better performance status, preserved liver
function, low volume, and no comorbidities.2
Chemotherapy is the recommended treatment
option for extranodal diffuse large B-cell lym-
phoma in general, making it a choice also for
the treatment of PHL when it is diagnosed pre-
operatively.31 Chemotherapy can be used either
as an adjunct to surgery or as a single modality.
In a review by Avlonitis and colleagues, a medi-
an survival of 20.7 months, ranging from 10-
123.6 months has been described in 14
patients treated surgically followed by adjuvant
chemotherapy.13 Adjuvant radiation therapy, or
a combination of adjuvant chemotherapy and
radiation, have been utilized in some studies.32
Early and aggressive anthracycline-based com-
bination chemotherapy may result in pro-
longed remissions in properly selected PHL
patients.2 The addition of rituximab, a
chimeric monoclonal antibody against the
CD20 B-cell antigen, to the CHOP regimen
increases the complete-response rate, and pro-
longs event-free and overall survival in elderly
patients with diffuse large-B-cell lymphoma,
without a clinically significant increase in tox-
icity.33 Combination chemotherapy was admin-
istered to 30 patients (73.2%) in our study,
although chemotherapy regimens differed
according to the date of diagnosis and the cen-
ter. The majority of patients received CHOP-
like regimens.
Most of the PHL patients had poor prognos-
tic features that include advanced age, consti-
tutional symptoms, elevated liver enzymes,
and comorbid diseases.2 The median survival
varies considerably in the literature, and
reported survival ranges from 3-123.6
months.13 In our study, the median survival
was 163 months, which was higher than previ-
ously reported rates. In a study by Page and col-
leagues, reviewing the experience of MD
Anderson Cancer Center, 24 PHL patients were
treated with chemotherapy and the overall 5-
year survival was 83%.9 The 5-year survival
rate in our study was 77%.
The absence of fever and presence of weight
loss and low hemoglobin levels were found to
be the worse independent prognostic factors
influencing the outcome. In univariate analy-
ses, it is interesting to note that among the B-
symptoms, fever (P=0.03) and night sweats
(P=0.24) seemed to have a better influence
but weight loss (P=0.14) a worse influence on
the outcome. In general, fever is a result of
immune response by the body to a foreign
invader. The fever response is executed by
integrated physiological and neuronal circuit-
ry, and confers a survival benefit during infec-
tion.34 A major goal of cancer immunology is to
stimulate the generation of long-lasting, tumor
antigen-specific immune responses that rec-
ognize and destroy tumor cells, and accumulat-
ing evidence indicates that survival benefits
are accorded to individuals who achieve an
increase in body temperature (i.e., fever) fol-
lowing infection.35
Conclusions
In this retrospective multicenter RCN study,
patients with PHL had a relatively better prog-
nosis than those reported elsewhere. It is
important to recognize this rare disease entity,
as it responds to therapy, and has a better prog-
nosis than hepatocellular carcinoma or sys-
temic lymphomas secondarily involving the
liver. Multicenter prospective studies are still
warranted to establish treatment guidelines,
outcome, and prognostic factors. 
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